A detailed history of Summit Trail Advisors, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Summit Trail Advisors, LLC holds 2,747 shares of NBIX stock, worth $397,930. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,747
Previous 1,719 59.8%
Holding current value
$397,930
Previous $216,000 78.24%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$123.98 - $146.67 $127,451 - $150,776
1,028 Added 59.8%
2,747 $385,000
Q2 2025

Aug 14, 2025

BUY
$87.54 - $128.18 $150,481 - $220,341
1,719 New
1,719 $216,000
Q1 2018

May 21, 2018

BUY
$75.88 - $92.43 $1.22 Million - $1.48 Million
16,064 Added 10363.87%
16,219 $16,000
Q4 2017

Feb 14, 2018

BUY
$58.53 - $77.59 $9,072 - $12,026
155
155 $14,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Summit Trail Advisors, LLC Portfolio

Follow Summit Trail Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Trail Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Trail Advisors, LLC with notifications on news.